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Abstract
Purpose The Myeloma Patient Outcome Scale (MyPOS)
was developed to measure quality of life in routine clinical
care. The aim of this study was to determine its longitu-
dinal validity, reliability, responsiveness to change and its
acceptability.
Methods This 14-centre study recruited patients with
multiple myeloma. At baseline and then every two months
for 5 assessments, patients completed the MyPOS. Psy-
chometric properties evaluated were as follows: (a) confir-
matory factor analysis and scaling assumptions
(b) reliability: Generalizability theory and Rasch analysis,
(c) responsiveness and minimally important difference
(MID) relating changes in scores between baseline and
subsequent assessments to an external criterion, (d) deter-
mining the acceptability of self-monitoring.
Results 238 patients with multiple myeloma were recrui-
ted. Confirmatory factor analysis found three subscales;
criteria for scaling assumptions were satisfied except for
gastrointestinal items and the Healthcare support scale.
Rasch analysis identified limitations of suboptimal scale-
to-sample targeting, resulting in floor effects. Test–retest
reliability indices were good (R =[ 0.97). Responsive-
ness analysis yielded an MID of ?2.5 for improvement and
-4.5 for deterioration.
Conclusions The MyPOS demonstrated good longitudinal
measurement properties, with potential areas for revision
being the Healthcare Support subscale and the rating scale.
The new psychometric approaches should be used for
testing validity of monitoring in clinical settings.
Keywords Multiple myeloma  Health status  Rasch
analysis  Quality of life  Responsiveness
Introduction
Cancer is a major public health concern, being the second
leading cause of death worldwide [1]. With the ageing of
the society, cancer incidence is rising [2, 3]. Despite
advances in treatments, many cancer patients still face long
disease trajectories and incurable disease. Multiple mye-
loma, an incurable cancer of the bone marrow and the
second most common haematological malignancy [4],
exemplifies this changing face of cancer. Many myeloma
patients experience a more chronic disease trajectory,
coping with gradually progressing disease, interspersed
with intervals of stable disease with minimal or mainte-
nance treatment but lasting effects of high-dose
chemotherapy [5, 6]. This longer disease trajectory of
cancer and the intensive treatments have led to a need to
evaluate patient-reported outcomes in addition to tradi-
tional monitoring, such as response to treatment and toxi-
city profiles, in this condition.
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Patient-reported outcomes primarily comprise symp-
toms and health-related quality of life (HRQOL). Incor-
porating longitudinal assessment into routine clinical
practice has shown benefits such as better symptom con-
trol, improved patient-clinician communication and satis-
faction with care [7, 8]. In trials, serial assessment of
HRQOL incorporates the patient’s experience while mon-
itoring treatment safety and efficacy [9]. It also aids
prognosis in chronic conditions and in haematological
malignancy [10–12].
Despite these benefits, few measures are designed for
monitoring HRQOL in routine clinical settings [13, 14]. A
systematic review of 13 generic and disease-specific
HRQOL measures in multiple myeloma [13] found no
single tool developed or validated for this purpose. Con-
sequently, the Myeloma Patient Outcome Scale (MyPOS),
a questionnaire to measure disease-specific HRQOL and
palliative care concerns, was developed and validated in a
cross-sectional sample of 380 community and inpatient
myeloma patients in the United Kingdom (UK) [15].
However, the clinical utility of the MyPOS in form of
longitudinal validity and reliability [16–19] still needs to be
established.
The psychometric criteria for longitudinal monitoring
validity are still ill-defined. Traditional psychometrics and
associated guidelines focus on usages of assessment or
screening [20–22]. The notable exception is McHorney’s
study of individual patient-monitoring in which the fol-
lowing criteria were proposed [23]: (i) practical features
(brief measures, easy administration, easy score interpre-
tation), (ii) breadth of health measured (variety of health
concepts with assessing the full range of health from dis-
ability to well-being), (iii) depth of health measured
(minimal floor and ceiling effects), (iv) precision for cross-
sectional assessment (precise reliability estimates, e.g.
Cronbach’s alpha, with small standard error of measure-
ment) (v) precision for longitudinal monitoring (high
reproducibility/test–retest reliability with small standard
error of measurement), and (vi) validity (satisfactory con-
vergent/divergent validity, high responsiveness/sensitivity
to clinical change and definition of individual patient
application, e.g. screening, monitoring, decision-making,
tested). The authors also recommend more stringent
benchmarks for measurement errors to fit the longitudinal
use of measures [23]. Building on this work, we propose to
extend McHorney et al’s framework by incorporating new
psychometric approaches, particularly Rasch analysis
[24, 25] and Generalizability theory [26–28], to further test
some of their six quality criteria for longitudinal monitor-
ing applications. Particularly Generalizability theory has
been used successfully in psychological studies that mon-
itored emotional changes [29]. Both techniques are suit-
able since they address the limitations of classical test
theory (CTT) by providing individual item information,
information on item invariance and person-level indicators
that help understand floor and ceiling effects, understand-
ing sources of measurement error, and the ability for dis-
criminating among different patient groups (i.e. disease
severity) [24, 25, 28, 30]. In particular, we propose to
extend analysis for criteria (iii), depth of health measured,
(iv) precision for cross-sectional assessment, and (v) pre-
cision for longitudinal monitoring by using person-item
targeting in Rasch analysis to further understand floor and
ceiling effects, and to use the variance decomposition
method for forming reliability indices beyond simple test–
retest reliability, to understand how reliable the use of an
instrument is in the situation of screening HRQOL at one
point in time, monitoring HRQOL over time and detecting
change over time (iv and v, [29]).
We aim to examine the longitudinal validity and reli-
ability of the MyPOS. The objectives are: (a) to evaluate
the validity of the MyPOS and its scale in myeloma
patients at different stages in their disease trajectory,
(b) to determine the reliability of the MyPOS over time
(test–retest reliability) within a Generalizability frame-
work, (c) to determine the responsiveness and clinical
significance of changes in quality of life scores and sub-
scale scores and estimate the minimal important change
(MID), both for patients who deteriorated and improved,
and (d) to explore the acceptability of frequent self-
monitoring of HRQOL.
Methods
Study design and participants
This multi-centre, prospective longitudinal study recrui-
ted patients with multiple myeloma at different disease
stages. Patients were enrolled in the study from March
2014 until July 2015. Inclusion criteria were as follows:
older than 18 years, confirmed diagnosis of multiple
myeloma that had been disclosed to the patient and
capacity to give informed written consent. Patients who
were too unwell, distressed or symptomatic to participate,
as judged by their clinical team, were excluded, as were
patients with severe neutropenia or for whom myeloma
was not the most important health problem. Patients were
recruited from 14 hospital trusts in the United Kingdom,
both from secondary and tertiary centres. Study proce-
dures followed the guidelines of the Helsinki Declaration.
Ethical and research governance approvals were obtained
from the Central London Ethics Committee (13/LO/1140)
with further local Research and Development approvals
from all participating National Health Service (NHS)
hospital trusts.
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Procedures
Consenting patients were invited to complete questionnaires
at baseline and then every two months for a total of five
assessments and a maximum follow-up time of eight months
post-baseline. The first questionnaire was given to patients
when they attended outpatient clinics. Subsequent ques-
tionnaires were sent via mail, with a self-addressed, pre-
stamped envelope provided for return, a pen and a sweet to
boost participation [31]. Patients were followed, if possible,
if they moved to a nursing home, hospital or hospice. We
sought information about any deaths that occurred.
Questionnaires
Participants completed the MyPOS [15]. The MyPOS is a
module of the Palliative Care Outcome Scale (POS)
[32–34], extended by myeloma-specific concerns. It com-
prises a list of 13 symptoms and 20 items about quality of
life or palliative care concerns. The POS is a prominent
measure of palliative care concerns. During the develop-
ment phase of the MyPOS, in focus groups with experts as
well as in cognitive interviews with patients, it was opted
to adapt an existing questionnaire rather than develop a
new one [35]. In the cognitive interviews, a clear prefer-
ence for the item style and response options of the POS was
shown. Also, some of the generic POS items were used in
building the MyPOS since they measured relevant domains
of myeloma-related quality of life [35]. In an attempt to
harmonise disease- or condition-specific measures of the
POS, the Integrated Palliative care Outcome Scale (IPOS)
[36] was formed and it was opted by the POS research
group to convert all disease-specific POS measures to a
common, module-style format (similar to the European
Organization for the Research and Therapy of Cancer
(EORTC) quality of life and the Functional Assessment of
Cancer Therapy (FACT) quality of life questionnaires
[37, 38]). At the same time, the POS was revised and
especially its original two symptom items were extended
by a list of symptoms prevalent in palliative care patients.
The revised IPOS now contains 17 items. It is a valid and
reliable measure [36]. Just prior to commencing this lon-
gitudinal validation study, the MyPOS was converted to
become a module of the IPOS. All symptom (generic and
myeloma-specific) and general palliative care-related
problem items (list extended by four general palliative
care-related concerns) now form the first part of the
MyPOS and the myeloma-specific concerns form the third
part of the questionnaire (for original and revised version
see Supplemental Figs. 1, 2). The MyPOS used in this
study therefore contains six additional IPOS items not
contained in the version validated in Osborne et al. (2015)
[15].
Items are scored on a five-point Likert scale. For
symptom items, the scale ranges from 0 ‘not at all’ to 4
‘overwhelmingly’. For all other items, response options
labels are question-specific with 0 signifying no problems
and 4 signifying a high amount of problems (Supplemental
Fig. 3 shows the response options for each scale of the
MyPOS). Content and construct validity of the original
MyPOS have been established in a clinically representative
sample [15, 35].
To evaluate the responsiveness and minimal important
change on the MyPOS, an independent question to assess
the degree of change was used. This global rating of
change question (GRC) [22, 39] asked ‘Has your overall
quality of life changed since the first time you completed
this questionnaire?’, with patients indicating whether their
quality of life had got worse, stayed the same, or had
improved. The GRC question was part of each follow-up
assessment.
The questionnaire sent at the third assessment contained
three open-ended questions to explore the acceptability of
frequent self-monitoring. The questions concerned the
suitability of the MyPOS for monitoring quality of life, the
potential usefulness of monitoring quality of life and how
results could be used by patients and clinicians.
Statistical analysis
Table 1 provides an overview of analyses methods per
objective, following the McHorney et al. framework [23],
and detailing the criteria that were used for establishing fit
and validity/reliability. All quantitative data analyses were
conducted in SPSS v.22 [40], lavaan package in R [41] and
partial credit Rasch models were run in RUMM2030 [42].
Patients with three or more missing MyPOS questionnaires
at the follow-up time points were excluded from statistical
analyses. If more than 50% of responses within a scale
were missing from one questionnaire, it was removed from
the analysis. Missing data in the confirmatory factor anal-
ysis were imputed using a multiple imputation approach
[43]. Responsiveness analyses and Rasch analysis used a
complete case analysis without imputation of missing data.
For construct validity (objective 1), re-evaluating the
subscale structure defined in the initial validation [15] was
necessary due to the sample-dependency of CTT approa-
ches [58]. Confirmatory factor analyses contrasting three
models to find best fit of the data were used: (i) a uni-
dimensional model (one factor) solution, (ii) three-factor
solution replicating the solution from the initial validation
[15] with symptom and functioning items loading on one
factor, separate from factors emotional response and
healthcare support, and (iii) an adapted three-factor solu-
tion with all functioning items loading onto the emotional
response factor, resulting in three subscales Symptoms,
Qual Life Res
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Table 1 Overview of measurement properties and criteria for assessing longitudinal validity and reliability
Measurement property Statistical methods
Objective 1: Further validity of the MyPOS
Diagonally weighted least squares
(DWLS) confirmatory factor analysis
using R lavaan package [41]
Goodness-of-fit indices:
(a) v2/df[ 2 [44]
(b) Comparative fit index (CFI) of C 0.90 [45]
(c) Root mean square error of approximation (RMSEA) of B 0.06, 90% confidence interval
0.05–0.08 [45]
(d) Non-normal fit index (NNFI) of C 0.95 or normal fit index (NFI) of C 0.95 [45]
Checks of unidimensionality of three separate subscales analysed with Rasch analysis: principal
component analysis and paired t-tests in RUMM2030 [46, 47]:
(a) RMSEA\ 0.08 [48]
(b) CFI[ 0.90 [49]
(c) Tucker-Lewis Index (TLI)[ 0.90 [45]
Floor and ceiling effects via descriptive
and Rasch analysis
Data completeness and distribution of item responses
[15% of responders at the lower or upper end of the scale [16]
Rasch analysis: Scale-to-person targeting, the ability of the scale to cover the whole range of person
estimates, shown on the person-item threshold distribution map [29]
Scaling assumptions via Rasch analysis (RUMM 2030) [42]
Fit to the Rasch model Fit to the Rasch model Non-significantV2-test [50] and RMSEA\ 0.2 [45]. However, large sample
size can inflate the V2 value and increase the likelihood of identifying misfit [45]. A partial credit
Rasch model was used
Fit of individual items Individual item fit Fit residual range -2.5 to ?2.5 [50]. The residuals indicate the level of agreement
between the observed and expected responses with perfect fit being given if a mean residual is zero
with a standard deviation falling between -1 and ?1. Positive fit indices above ?2.5 show misfit
to the model, negative fit indices below -2.5 indicate redundancy of items. Item characteristic
curves were examined for graphical item fit
Person fit Person fit Same criteria as item fit
Reliability Reliability: Person Separation Index (measure of internal consistency in Rasch analysis) C 0.70 [51]
Response options Response options: Category probability curve maps for each item examined for disordered answer
options, signifying ambiguous labelling or abundance of response options
Redundant items Redundant items Residual correlation matrix, identifying pairs of items with high correlation
coefficients (C0.3) [50]
Objective 2: Test–retest reliability/item invariance of the MyPOS
Test–retest reliability using
Generalizability theory
Restricted maximum-likelihood variance decomposition (VARCOMP) with participants and
interaction terms as random factors and items and days as fixed factors. The variance associated
with each component of variation, systematic between-person differences in mean item levels, true
within-person change over time, idiosyncratic item responses and random measurement error, is
partitioned [27, 28]. These variance estimates are used to form indices of the reliability for
discriminating between-persons (between-person differences) and within-person change
Four generalizability coefficients (all[0.5 [29]):
R1F Reliability of assessment/screening (Is the MyPOS reliable at each assessment?)
R1R Reliability of discrimination (Can the MyPOS reliably distinguish between persons over time?)
RKF Test–retest reliability (Is the MyPOS reliable over time?)
Rc Within-person reliability of change (Can the MyPOS assess change in one person over time?)
It should be noted that determination of test–retest reliability within Generalizability theory is a
model-based approach that derives reliability indices from variance decomposition as an
alternative way to intra-class correlation coefficients. Analysis of test–retest reliability was based
on the subgroup of stable patients as indicated by the global rating of change (‘‘unchanged’’—see
objective 3, responsiveness)
Item invariance using Rasch analysis Differential item functioning (DIF) via a two-way ANOVA of standardised residuals with
Bonferroni correction for type I error [52]; assessing whether item mean scores showed significant
change over all five assessments [50]
Significant interaction between class interval (level of quality of life) and time indicates a non-
uniform DIF and an unstable, unreliable item
Qual Life Res
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Functioning and Emotional response, and Healthcare sup-
port. Scaling assumptions of the total MyPOS score, sub-
scale scores and individual item scores were evaluated
using Rasch analysis. A partial credit Rasch model was
fitted to each subscale, Symptoms (13 items), Emotions (17
items) and Healthcare Support (3 items), separately.
Floor/ceiling effects and distribution of item responses
were checked using descriptive statistics and Rasch anal-
ysis (person-location maps). The presence of floor or
ceiling effects is indicated in the person-location map by
mean item location scores not matching the whole range of
person locations at the lower or upper end of the scale [59].
This indicates either items missing from the measure to
represent very good or poor HRQOL, or indicates that the
sample used for evaluation of the measure is not well tar-
geted to comprise all levels of severity that the MyPOS
measures [50]. For establishing the test–retest reliability
and invariance of the MyPOS (objective 2) for participants
that indicated they did not experience a change in their
condition over time, the Generalizability theory framework
was used [26–28]. Four generalizability coefficients [29]
were computed (see Table 1). Item invariance was further
tested using Rasch analysis following Hobart et al.’s [58]
approach using differential item functioning (DIF). DIF is
an indicator of items not performing in a stable/invariant
way since the expected values on the item are not the same
for all subgroups in the sample (i.e. groups of different
disease severity or functional ability) [58]. Objective 3,
establishing the responsiveness to change and the minimal
important difference for the MyPOS, followed guidelines
by Guyatt [55] and used a combination of anchor-based,
distribution-based approaches. For responsiveness, we used
the GRC to identify patients that experienced change over
time, with categories improved, unchanged and deterio-
rated to examine the differences in mean score changes
between each time point and baseline (T2 to T1, T3 to T1,
T4 to T1, T5 to T1). We determined ROC curves separately
for improvement and deterioration (improved vs. stable or
deteriorated vs. stable) for total MyPOS score and the three
subscale scores. For objective 4, we analysed participants’
written comments in the open-ended questions of the
MyPOS using thematic analysis [57].
Results
Characteristics of patients and questionnaire
completion
250 patients were recruited of whom 238 completed the
questionnaire at baseline. Mean age was 68.5 (range
34–92 years), mean time post diagnosis was 3.3 years with
139 (25.5%) patients who had been living with myeloma
5 years and longer (see Table 2). 199 participants
Table 1 continued
Measurement property Statistical methods
Objective 3: Responsiveness and minimal important difference (MID(for MyPOS
Responsiveness GRC to categorise patients into:
(a) improved overall QOL
(b) deteriorated overall QOL
(c) unchanged
Differences in mean score changes between each time point and baseline were assessed and graphed.
The adequacy of the anchor was assessed via Spearman correlation [17]
MID: anchor-based approach Receiver-operating characteristic curve (ROC) to determine optimal cut-off points separately for
improvement and deterioration, according to GRC ratings [53].
MID: cut-off point on ROC for which the sum of percentages of false-positive and false-negative
classifications [(1-sensitivity or true positive rate) ? (1-specificity or false positive rate)] is
smallest [39].
Significance of the area under the curve with a p value[ 0.5 indicates changes on the MyPOS
scores are associated with the gold standard GRC criterion [39].
Graph of distribution of change scores, MIDs and 95% CIs [54]
MID: distribution-based approach Standard deviation at baseline used to estimate MID [55]
Following Cohen’s criteria [56], small changes (0.2 9 SD), moderate changes (0.5 9 SD) and large
changes (0.8 9 SD) were computed. A moderate effect size change was designated as the MID
[55]
Objective 4: acceptability of monitoring
Acceptability Thematic analysis of responses to open-ended questions about views on self-monitoring and data
feedback were analysed using thematic analysis [57]
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completed time point 2 (83.6%), 171 completed time point
3 (71.8%), 150 completed time point 4 (63%) and 125
(52.5%) completed the last time point 5 questionnaire. Of
the 113 patients lost to follow up, 9 had died, 17 had been
feeling too unwell to continue with the study, 2 had moved,
and 86 gave no reason for discontinuing the study. 12
questionnaires were lost in the mail.
At baseline, 3.3% of responses in returned question-
naires were missing. The number of missing responses
reduced over time: 1.2% at time point 2, 0.7% at time point
3, 0.7% at time point 4 and 0.9% at last follow-up time
point.
Confirmatory factor analysis of the MyPOS
and Rasch scaling
Confirmatory factor analysis
Factor analysis confirmed a three-factor structure but with
functioning items now loading onto the Emotional
response factor (solution iii). The fit indices indicated a
satisfactory model fit. Although the X2 test was significant,
the RMSEA (0.056; 90% CI 0.050–0.063) and the CFI
(0.942) were satisfactory. When compared to the uni-di-
mensional solution, the three-factor solution performed
best. The three factors together explain a total of 42.2% of
the variance with the three subscales explaining 28.1, 7.2
and 6.9%, respectively. All items loaded above 0.40 on
their respective subscales, except item 12 (‘‘Tingling in the
hands/feet, 0.378) and item 29 (‘‘Worry about sex life’’,
0.189) (see Supplemental Table 1).
Rasch analysis
Overall fit of the data to the Rasch model for each subscale
was given (see Supplemental Table 2). The range of item
locations and item thresholds logits for all three subscales
indicated that items mapped out a measurement continuum.
The Symptom subscale had the widest range of item
locations from -1.16 to ?1.92 logits. The Healthcare
support subscale had a range of item thresholds from a
maximum of -3.07 to ?5.28 logits. Regarding individual
item fit, item 12 ‘Tingling in hands/feet’ was the only item
showing misfit in the Symptoms subscale with a fit residual
of ?2.68. In the Emotional response subscale, three items
(‘Sharing feelings with family/friends’, ‘Worry about sex
life’, ‘Information about the future’) showed misfit to the
Rasch model (fit indices ranged from ?2.52 to ?3.16). All
items in the Healthcare support subscale fitted the Rasch
model (see Table 3). Examination of graphical fit via item
characteristic curves confirmed good fit to the Rasch model
for 30/33 items, except for ‘Tingling in the hands/feet’,
‘Worry about sex life’ and ‘Information about future’ (see
Supplemental Fig. 3). These show a slight under-discrim-
ination, indicating difficulties to stratify participants
according to different levels on the latent variable HRQOL.
Regarding item response options, thresholds were
ordered for 12/33 items, but for 21/33 items the 5-point
scale did not work in a linear way (see Supplemental
Table 2). For ten of these items, people appeared to have
difficulty discriminating between the last two to three
categories, thus distinguishing a moderate problem from a
severe or overwhelming one. For 11 items, people seemed
to have difficulty discriminating between the first two
categories (‘not at all’ and ‘slight’/’moderate’). Fit for all
items improved after removing extreme persons and
rescaling the MyPOS items showing misfit and disordered
thresholds to a 3-point Likert scale by combining cate-
gories ‘‘A little’’ and ‘‘Moderate’’, and combining ‘‘Sev-
ere’’ and ‘‘Overwhelming’’, the two highest response
categories. After rescoring, all items on the Symptom
subscale showed ordered thresholds. In the emotional
subscale, item 19 (Having enough information about the
illness’’) and item 33 (‘‘Having enough information about
what might happen in the future’’) retained disordered
thresholds, as did item 32 (‘‘Doctors/nurses show care &
respect’’) on the Support subscale. Chi-square test statistics
and the person separation index did not improve on this last
subscale after rescoring and the Support subscale does not
fit the Rasch model.
Some item redundancy was present for seven pairs of
items that had residual correlations exceeding r\ 0.30
(3% of total correlations). The following item pairs showed
potential redundancy: Nausea–Vomiting (r = 0.37), Prob-
lems with feeling at peace-Depression (r = 0.36), Prob-
lems with sharing feelings with family–family anxiety
(r = 0.39), Hobbies-Usual activities (r = 0.36), Worry
about illness worsening-Anxiety (r = 0.35). Two pairs of
items in the Healthcare support subscale correlated highly:
Contacting doctors for advice—knowledge of staff
(r = 0.82) and Contacting doctors for advice-Doctors
showing respect (r = 0.55).
Floor and ceiling effects
For most items, all response options were endorsed. How-
ever, 10/33 items (‘Nausea’, ‘Vomiting’, ‘Poor appetite’,
‘Sore or dry mouth’, ‘Diarrhoea’, ‘Drowsiness’, ‘Tingling in
the hands/feet’, and three items in the Healthcare support
subscale) had floor effects with participants not using the
two highest levels. These were also the items with the most
skew. Up to 18/33 items had percentages of[50% of par-
ticipants choosing the option ‘Not at all’. The MyPOS total
score and subscale scores showed a normal distribution
except for the Healthcare support subscale which demon-
strated skew[2.5 at each time point.
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In Rasch analysis, 14 person fit residuals exceeded the
recommended range of -2.5 to ?2.5 (-3.68 to 3.55);
implying that approximately 6% of people gave responses
not in keeping with expected scores. Scale-to-scale tar-
geting was suboptimal. Figure 1 shows the person esti-
mation-item location distribution for the three MyPOS
subscales. The sample covers the bulk of possible item
locations on the MyPOS Symptom. Some mistargeting
exists for the Emotional response subscale. The scale did
not cover the sample in the Healthcare support scale,
indicating floor effects.
Reliability of the Myeloma Patient Outcome Scale
The Person separation indices implied good sample sepa-
ration and high reliability (Supplemental Table 2), except
for the Healthcare support subscale consisting of only three
items. This was confirmed by values of Cronbach’s alpha
that did not exceed a lower bound of 0.795.
Variance decomposition shows that the largest compo-
nent is error variance. Next, variance is due to participants
experiencing change between assessments (Table 4),
reflected by high between-person variation and interaction
terms for person x time and indicating that participants
experienced different HRQOL trajectories over the period
of eight months. The generalizability coefficients (Table 4)
show that (a) reliability of screening was reasonable to
good (RIF 0.55 to 0.73), (b) discrimination was lower
(RIK\ 0.50), except for the Healthcare support scale,
(c) test–retest reliability of the MyPOS was excellent
Table 2 Demographic and clinical characteristics of 238 patients
with myeloma included in the study
Variable
Age, mean ± SD (range) 68.5 ± 10.5
(range 34–92)
Men, N (%) 147 (61.8)
Married, N(%) 170 (71.4%)
White background, N(%) 220 (92.4%)
Education level, N(%)
Secondary school 137 (57.5)
Technical qualification 52 (21.8)
University 41 (17.3)
Working, N(%) 41 (17.2)
Type of myeloma, N(%)
IgA or IgG 180 (78.6)
Light chain disease 39 (16.4)
Other 9 (3.8)
ISS stage at diagnosis, N(%)
I 68 (28.6)
II 41 (17.2)
III 52 (18.6)
Time since diagnosis (in months), mean (SD) 39.1 (38.2)
Disease stage, N(%)
Newly diagnosed 38 (15.9)
Stable/plateau 128 (53.8)
Relapsed/progressive/refractory disease 72 (30.3)
Currently receiving treatment, N(%) 118 (49.6)
Active therapy 80 (33.6)
Maintenance therapy 38 (15.9)
Intensity of treatments received, N(%)
Chemotherapy only 111 (46.7)
Chemotherapy and HSCT 76 (31.9)
Two or more HSCT 15 (6.3)
Lines of treatment received, mean (SD) 1.5 (1.2)
ECOG performance status, N(%)
0 Fully active 79 (33.2)
1 Restricted 104 (43.7)
2 Unable to work 33 (13.9)
3 or 4—Limited self-care/bed-bound 15 (6.3)
Charlson comorbidity index, mean (SD) 4.9 (1.5)
General symptom level (MyPOS), N(%)
0 3 (1.3)
1–5 70 (29.4)
6–8 65 (72.3)
9–15 92 (38.7)
Table 2 continued
Variable
Mean number of symptoms, Mean ± SD 7.4 ± 3.6
Total MyPOS, mean ± SD 26.0 ± 16.8
Initial induction and HSCT were counted as one single line of
treatment. Likewise, if during a line of treatment the anti-myeloma
therapy was changed due to unresponsiveness or side effects, this was
still counted as one line. If active treatment was followed by main-
tenance treatment, active and maintenance were counted as one line.
A treatment-free interval was defined by not receiving active or
maintenance anti-myeloma therapy, whereas supportive therapies
(e.g. bisphosphonates or anti-anaemia treatment) were possible
ECOG Eastern Cooperative Oncology Group performance status;
HSCT haematopoietic stem cell transplantation; IgA immunoglobulin
A; IgG immunoglobulin G; ISS international staging system for
multiple myeloma; MyPOS Myeloma Patient Outcome Scale; SD
standard deviation
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Table 3 Myeloma Patient Outcome Scale item fit statistics ordered by location (n = 238)
Item Label Threshold
ordering
Item
location
Standard
error
Item fit
residual
X2 p value Threshold after
collapsing
response
categories
Item fit
residual
after
reordering
p value
after
reordering
Subscale symptoms
1 Pain H -0.48 0.08 -0.01 1.5 0.674 – – –
2 Breathlessness H -0.44 0.09 0.65 4.6 0.201 – – –
3 Fatigue H -1.16 0.09 -1.28 7.2 0.067 – – –
4 Nausea 3 0.46 0.11 -0.49 3.7 0.294 0/1(A little ?
moderate)/
2(severe ?
overwhelming)
-0.82 0.209
5 Vomiting 3 1.92 0.15 -1.07 4.6 0.202 0/1/2 -1.76 0.028
6 Poor appetite 3 1.52 0.09 -1.34 3.2 0.357 0/1/2 -1.41 0.159
7 Constipation 3 -0.37 0.08 -0.43 2.5 0.472 0/1/2 -0.61 0.421
8 Sore or dry mouth H -0.17 0.09 1.07 4.3 0.229 – – –
9 Drowsiness H -0.27 0.09 -1.13 3.7 0.290 – – –
10 Poor mobility H -0.59 0.08 -1.13 6.5 0.091 – – –
11 Diarrhoea 3 0.22 0.10 0.89 5.5 0.138 0/1/2 0.71 0.367
12 Tingling in hands/feet H -0.41 0.08 2.68 16.7 0.001 0/1/2 2.39 0.011
13 Difficulty remembering 3 -0.21 0.09 0.25 1.5 0.687 0/1/2 0.64 0.339
Subscale emotional response
14 Anxiety H 0.06 0.08 -2.18 15.3 0.002 0/1/2 -1.80 0.006
15 Family anxiety H -0.26 0.07 0.87 0.7 0.864 0/1/2 0.53 0.974
16 Depression 3 0.29 0.08 -0.83 7.9 0.047 0/1/2 -1.32 0.035
17 At peace 3 -0.69 0.08 -1.69 13.9 0.003 0/1/2 -1.20 0.036
18 Sharing feelings 3 -0.03 0.07 2.52 3.6 0.308 0/1/2 2.49 0.041
19 Information 3 0.23 0.07 -0.13 2.6 0.453 0/1/2 -1.03 0.519
20 Practical matters 3 0.31 0.08 0.45 1.3 0.741 0/1/2 0.88 0.624
21 Usual activities 3 -0.26 0.07 0.21 1.7 0.639 0/1/2 -0.21 0.705
22 Hobbies 3 -0.66 0.06 0.81 8.5 0.037 0/1/2 -0.55 0.423
23 Quality time with family/
friends
H 0.26 0.08 -0.91 5.7 0.126 0/1/2 -1.06 0.301
24 Worry about sex life 3 0.17 0.08 3.16 27.6 0.001 0/1/2 2.79 0.001
25 Worry about infections 3 0.15 0.08 1.45 4.3 0.228 0/1/2 1.22 0.223
26 Worry about physical
appearance
H 0.29 0.08 -0.17 0.3 0.953 0/1/2 0.13 0.402
27 Worry about financial
situation
3 0.17 0.07 -0.02 3.0 0.391 0/1/2 0.44 0.285
28 Worry about illness worsening H -0.50 0.07 -1.64 8.4 0.038 0/1/2 -1.72 0.010
29 Coping with illness and
treatment
3 0.41 0.09 -1.93 19.3 0.001 0/1/2 -2.40 0.018
33 Information about future 3 0.06 0.07 2.99 19.4 0.001 0/1/2 2.79 0.044
Subscale: healthcare support
30 Contact for advice 3 -0.69 0.15 0.46 1.8 0.411 0/1/2/3 ? 4 1.27 0.109
31 Knowledge/skill of doctors 3 -0.14 0.17 0.25 5.3 0.069 0/1/2/3 ? 4 0.56 0.023
32 Care and respect 3 0.83 0.24 -0.20 4.8 0.092 0/1/2/3 ? 4 0.05 0.154
Bolded values indicate fit residuals outside the recommended range of -2.5 to ?2.5 or significant X2-values
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Fig. 1 Targeting of the sample
(person-item location
distribution maps) for the three
subscales Symptoms (first
panel), Emotional response
(second panel), and Healthcare
Support (third panel) Note the
figure shows the distribution of
person measurements (upper
histogram) against the
distribution of item locations
(lower histogram). People are
located along a continuum of
low quality of life (left-hand
side) to better quality of life
(right-hand side). Items are
located relative to their
difficulty: easier items
(representing lesser impact on
quality of life) on the right-hand
side, and the most difficult items
(required for a better quality of
life) on the left-hand side.
People outside the scales
measurement range (-2 to ?2
logits) indicate suboptimal
scale-to-scale targeting. A
ceiling effect is seen when the
person locations on the left-
hand side do not cover the item
locations below, meaning items
not discriminating in the portion
of the sample with high quality
of life
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(RKF[ 0.90), (d) MyPOS can reliably measure change in
individual patients over time (RC[ 0.60), except in the
Healthcare support subscale (RC = 0.42).
Item invariance via DIF analysis identified the items
‘Constipation’, ‘Drowsiness’, ‘Diarrhoea’ in the Symptom
subscale as unstable over time. In the Emotional response
subscale, only the item ‘Worry about infections’ showed
DIF. None of the items in the Healthcare support subscale
showed DIF (see Supplemental Table 3).
Responsiveness of the Myeloma Patient Outcome
Scale
The total MyPOS score correlated moderately with the
global rating scale (GRC, anchor) at every time point
(range: r = 0.312 to r = 0.482). 125 participants con-
tributed data for all five time points. Equal numbers of
participants experienced a change in quality of life for the
better or the worse, but the majority (about 60%) experi-
enced no change (see Supplemental Table 4). Figure 2
shows the plotted change scores across time points. Except
for the Healthcare support subscale, all mean change
scores and corresponding confidence intervals indicated an
improvement in MyPOS scores when patients classified
themselves as overly improved, and a worsening of
MyPOS scores when participants described their general
quality of life as deteriorated.
Table 4 Variance partitioning of MyPOS total and subscale scores and Generalizability reliability coefficients
Source of variance Total MyPOS Symptoms Emotions and functioning Healthcare support
var % var % var % var %
Person 0.11 12.5 0.097 12.7 0.177 17.1 0.05 20.0
Time point 0.143 16.2 0.164 21.4 0.108 10.4 0.005 2.0
Item 0.004 0.5 0.003 0.4 0.006 0.6 0.001 0.4
Person 9 time point 0.2 22.7 0.178 23.3 0.202 19.5 0.021 8.4
Person 9 item 0.083 9.4 0.066 8.6 0.143 13.8 0.087 34.8
Time point 9 item 0.007 0.8 0.006 0.8 0.009 0.9 0 0.0
.Error 0.334 37.9 0.251 32.8 0.393 37.9 0.086 34.4
Total 0.881 100.0 0.765 100.0 1.038 100.0 0.25 100.0
Standard error of measurement 6.9 3.2 4.9 1.1
Scale RIF RIR RKF RC
Screening Discrimination Test–retest reliability* Reliability of change
Total MyPOS
0.553 0.233 0.970 0.642
Symptoms subscale
0.587 0.218 0.974 0.680
Emotions subscale
0.632 0.338 0.978 0.607
Healthcare support
0.734 0.591 0.986 0.423
* Test–retest reliability is based on patients who indicated their QOL as stable on the global rating of change
Fig. 2 Responsiveness of the total MyPOS change score over
8 months post baseline. Note a negative change score on the total
MyPOS denotes an improvement in quality of life
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Table 5 lists the optimal cut-off points (MIDs). For
patients who reported they had improved, the MID for the
total MyPOS score was 2.5. The subscale MIDs were 1.5
for Symptoms, 4.5 for Emotional response and 0.5 for
Healthcare support. MIDs for deterioration were similar to
those for improvement, with an MID of 4.5 for the total
score and MIDs of 2.5, 3.5 and 0.5 for the subscale scores.
The range of MIDs is much larger derived from the dis-
tribution-based approach, with estimates ranging from a
minimum of 3.4–13.4 in the total score and 0.3–9 in the
subscale scores (Table 5). Further examination of mis-
match between the two methods and uncertainty around the
MID revealed greater misclassification for improvement
than for deterioration (see distribution graph for total
MyPOS, Supplemental Fig. 3). The area under the ROC
curve predicting improvement or deterioration was signif-
icantly greater than 0.5 (p\ 0.01) for the total MyPOS
change score and all subscale scores except the Healthcare
support subscale.
Acceptability of frequent self-monitoring
for patients
46% of participants thought the MyPOS to be a feasible tool
for monitoring symptoms and problems/concerns over time.
23.9% of patients did not believe it was acceptable to
complete the MyPOS regularly before clinic visits. 30% of
responses were missing due to drop-out at this time. Con-
cerns about acceptability fell into two categories: (a) those
who thought it unfeasible to monitor changes because their
condition changed on a daily basis and a questionnaire could
not capture these minute alterations; and (b) those who felt
that their clinical team monitored their condition regularly
and a questionnaire would duplicate information. Linked to
both of these were concerns regarding overall burden,
especially when receiving treatment within a clinical trial
with regular data collection, and associated cost. Positive
statements included the belief that monitoring would help to
focus on the symptoms and problems over time, something
which these patients felt was often disregarded or over-
looked in consultations: ‘‘It would help the patient to focus
on their treatment, difficulties and problems. We are not
always aware that some problems and side effects are related
to medication and treatment and try to ignore them’’. (Fe-
male participant with relapsed disease)
Discussion
In the CTT and Rasch psychometric analysis, the MyPOS,
a disease-specific measure of quality of life and palliative
care concerns in multiple myeloma, presented as having
adequate construct validity and reliability for certain
subscales and items. For example, in the Rasch analysis
items mapped out a measurement continuum in all three
subscales. In terms of suitability for longitudinal monitor-
ing, it had excellent test–retest reliability as well as reliably
measuring change and being responsive. The MyPOS was
able to discriminate between subgroups of patients longi-
tudinally. However, some symptom and health care support
items with floor effects, suboptimal scale-to-scale targeting
and disordered thresholds point towards areas for revision.
These revisions in particular concern the third subscale,
Healthcare support, which overall had very substantial
floor effects in the items, high inter-item correlations and
thus item redundancy. Further targets are items in the
Emotional Response subscale, particularly items 15
(‘‘Family anxiety’’) and 18 (‘‘Sharing feelings with family/
friends’’), item 14 (‘‘Anxiety’’) and item 28 (‘‘Worry about
illness worsening’’), item 21 and 22 (‘‘Usual activities’’/
’’Hobbies’’) and items 19 (‘‘Information about illness/
treatment’’) and 33 (‘‘Information what might happen in
the future’’). It is worth exploring whether the MyPOS
could be shortened by removing redundant items, which
might also improve model fit in the factor analysis, and
whether a two-factor structure (after removal of the
Healthcare Support items) provides a better fit to the data.
Any revisions of the MyPOS must weigh information on
psychometric quality with considerations of clinical utility
of the item in the clinical context [60]. Revisions need to
balance considerations regarding content validity, clinical
usefulness and applicability of the item and take item
quality into account. A systematic review [13] identified 13
HRQOL instruments validated in myeloma, most of them
generic in nature (EORTC QLQ-C30, EQ-5D and 15D,
FACT-G, SF-36/12). This poses a problem as generic
questionnaires do not include disease-specific concerns and
symptoms and are therefore less suited for validly reflect-
ing patient experience [18]. The MyPOS was subsequently
developed following extensive patient interviews to close
the gaps in item coverage identified in other HRQOL
instruments, and to operationalise disease-specific HRQOL
according to a conceptual model developed from these
qualitative interviews [35].
We argue further that for clinical applicability, consid-
erations of test–retest reliability and responsiveness to
change for enabling the valid monitoring of patients in
clinical practice are paramount. However, this information
is often not available for disease-specific tools in multiple
myeloma. For example, an MID was only determined for
the EORTC QLQ-C30 and the two health state measures
EQ-5D and 15D [61, 62]. Subsequently, two new disease-
specific tools, the MDASI-MM [63] and the FACT-MM
[64], have been developed, but their validation has not yet
been completed or has not included longitudinal validity
testing to date. Another aspect lacking from validation
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studies is the investigation of scaling quality. One
notable exception is a study exploring Mokken scaling
stability of the EORTC QLQ-C30 across different sub-
populations of myeloma [65]. However, this analysis did
not provide in-depth information on each item and did not
look at item stability in a longitudinal context. For the
MyPOS, we provide both information on scaling quality
and longitudinal validity.
Regarding possible revisions of the MyPOS, the mea-
surement aim needs to be considered. For example, floor
effects in gastrointestinal symptoms may be observed for
most of the sample of a relatively stable myeloma popu-
lation not currently undergoing anti-cancer treatment or
receiving maintenance treatment only [66]. However, they
are important symptoms to monitor for the clinician to
make adjustments to the treatment plan should they sud-
denly become severe [67–70]. Inspection of the person-
item threshold maps shows that it is not the items in the
measure that do not cover the whole spectrum but rather
the sample that did not target all the item difficulty loca-
tions. Similarly, floor effects are commonly seen in
HRQOL and health satisfaction measures that are con-
structed with the intention of being applicable to a wide
range of disease severity levels [71–73]. This is even true
for disease-specific scales and was observed in the field-
testing of the EORTC QLQ-MY24 [74], subsequently
revised to 20 items. Floor effects in healthcare support
items may reflect the finding that respondents have more
positive experiences with the healthcare they received
affecting their willingness to participate in studies from the
outset [75]. However, while revision of the scale helped
improve the fit of items in the Symptoms and Emotional
Response subscale, these response scale adaptations should
be performed after further qualitative, cognitive interview
work [59, 76]. Another option is to extend the range of item
difficulties to cover all levels of severity and impact of
myeloma on HRQOL by constructing item banks and
computer adaptive testing [77]. In our analysis, we tried to
combine the perspectives of traditional psychometric
approaches (confirmatory factor analysis, responsiveness
and MID) with modern item response theory for evaluating
the stringent criteria proposed by McHorney et al. [23] for
longitudinal individual patient monitoring. Using the new
approaches addresses shortcomings of CTT such as vali-
dating only total scores instead of single items in a measure
and yielding sample-dependent results [30]. The benefits of
Rasch analysis include item-level statistics and information
on how items can be improved to fit the application in a
specific sample [78]. Furthermore, generalizability theory
[26–28] allows an exploration of sources of variation in
item scores, which leads to establishing various reliability
indices to distinguish different scenarios of use, i.e. using
HRQOL measures for screening (single application) or for
monitoring (application to track outcomes over time in an
individual). This extends the limited exploration of test–
retest reliability in CTT approaches [22]. The new psy-
chometrics are proposed as extensions to the original
operationalisations of measurement quality criteria that
were proposed by McHorney et al. [23] in their seminal
paper. They can potentially offer additional information on
sources of floor & ceiling effects and, due to Rasch analysis
yielding information on the full range of the construct
being measured, sources of problems with the coverage of
constructs and diverse patient groups. The same is true for
Generalizability analysis that provides a fine-grained pic-
ture of sources of measurement error beyond the random
measurement error and can therefore help understand
problems with precision of measurement in the cross-sec-
tional and the longitudinal application [27, 28]. However,
especially the latter approach to reliability assessment and
the indices proposed by Cranford et al. [29] are limited by
not being used widely in the literature which makes their
interpretation difficult. For example, it is not clear whether
thresholds for acceptable ICC estimates as proposed by
McHorney et al. [23] are applicable for the screening,
discrimination and reliable change index proposed in this
paper [29]. Further research is needed to explore this issue.
Moreover, we used Cranford et al.’s [29] method in a sit-
uation of a less intensive longitudinal design, with far less
frequent measurement than was employed in their diary
study. Therefore, the analysis of sources of variation
stemming from different time points is not as detailed as in
their original analysis.
Applying the framework of quality criteria for individ-
ual patient-monitoring to the MyPOS yields the following
assessment of its suitability for this application. Regarding
(i) practical features, survey administration is well below
15 min [15], however, the number of items is rather high
for a clinically applicable tool [18]. The analysis of breadth
of health measured (ii) yields good dimensionality of the
measure and coverage of all aspects of disease-related
QOL according to the theoretical model [15], however,
scale revisions indicated by low factor loadings, item
redundancy and poor fit of the Healthcare Support subscale
call for further exploration of dimensionality. Criterion
(iii), the depth of health measured, was partially fulfilled
with floor effects showing in 10/33 items and person-item
targeting analysis within Rasch modelling suggesting fur-
ther analysis in more severely affected samples. Criteria
(iv) and (v) pertaining to reliability were assessed slightly
differently by extending suggested analyses of Cronbach’s
alpha for cross-sectional reliability and test–retest relia-
bility by Rasch analysis and Generalizability theory, and by
omitting standard error of measurement as a quality crite-
rion. Although the actual size of the coefficient that should
be obtained is unclear, the rigorous criterion for reliability
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([0.95) set by McHorney et al. [23] was achieved for all
subscales in longitudinal analysis, but not for cross-sec-
tional reliability (screening & discrimination application,
Cronbach’s alpha). Validity (vi) in terms of cross-sectional
construct validity and responsiveness to change yielded
good sensitivity to change values. Further convergent and
divergent validity assessment is reported in the initial
validation of the MyPOS [15].
One of the most important features that makes a scale
suitable for monitoring purposes is its responsiveness to
change [19]. Our MIDs for improvement and deterioration
were smaller than the MIDs reported by Kvam and col-
leagues for the EORTC QLQ-C30 for patients with mul-
tiple myeloma [62]. Their MIDs range from 6 to 17 points
for improvement and 12–27 points for deterioration, a
small to medium change [62]. This discrepancy might arise
from the different nature of the QLQ-C30, a generic
measure, with absolute higher values of meaningful change
[78–81]. The large baseline standard deviations and the
amount of misclassification that was seen imply that not
enough patients in our sample experienced a substantial
change and that there further exists imprecision in the
anchor in classifying participants into improved and dete-
riorated. This is a commonly reported problem with the
ROC-curve based method of MID [54, 82] which, as a
diagnostic approach, would require a bias-free and precise
gold-standard anchor. However, in the absence of guidance
regarding construction of global rating scales this situation
might not easily be rectified.
The first limitation of our study is the use of consec-
utive enrolment, resulting in a convenience sample. The
strength lies in its greater clinical representativeness that
counteracts the effect of sampling younger and fitter
patients if validation is part of a clinical trial [66, 83].
However, since we recruited from outpatient clinics or
day centres, we potentially missed patients feeling too
unwell to participate in a longitudinal survey. This was
the first study to use Generalizability theory. This
approach for evaluating sensitivity to change normally
requires frequent assessments [29]. However, due to
patient burden this was not feasible. The reliability
coefficients may be an underestimation of the true lon-
gitudinal reliability of the MyPOS. Furthermore, since
this approach is relatively new, there are no guidelines as
to the size of the coefficients. Confirmatory factor analysis
used the DWLS approach to account for non-normality
and the ordinal nature of the response scale in the
MyPOS. However, although this approach has been
reported as robust in samples of above 200, a caveat is its
use in situations were missing data is missing not at
random [84]. Baseline data was used for confirmatory
factor analysis with missingness likely not due to sys-
tematic item nonresponse or non-random mechanisms.
However, low factor loadings of some items might be due
to systematic bias, i.e. for item 24 ‘‘Worry about sex life’’,
with effect on model fit. Different groupings of func-
tioning items on subscales in the reported factor analysis
compared to the initial factor analysis reported in Osborne
et al. [15] are most likely due to changing descriptive
labels of the rating scale of the symptom items to adapt
the MyPOS to the overall item and scaling format of the
IPOS [32, 36], of which it is a module. In the adapted
version of the MyPOS, the rating scale for the symptoms
only lists the severity of impairment but not the added
descriptor ‘‘impaired activity or concentration’’. This
change might have affected other aspects of construct
validity, which likely necessitates a re-validation of
aspects of construct validity of the symptom subscale. For
the anchor-based MID approach, there is no consensus for
the amount of categories and the exact phrasing of the
global rating scale of change. Authors have used 3-point
[56] to 15-point scales [85]. We tried to balance the
potential lack of sensitivity of fewer response options
with the need to arrive at a valid measurement of change
presenting only so many levels which patients can ade-
quately discriminate. Since we asked patients to compare
a change in their condition always to the first assessment,
recall bias may have affected at least part of the sample.
Furthermore, the wording of the rating scale might not
present a valid global assessment of change in quality of
life as operationalised in the multi-dimensional, disease-
specific MyPOS. The validity of the global rating of
change as a criterion for anchor-based derivation of the
MID is further pulled into question by the relatively low
correlation between anchor and change scores and the
MID not exceeding the SEM in all subscales.
Conclusion
This analysis supported the responsiveness and test–retest
reliability of the MyPOS, using a multi-centre outpatient
sample of patients at different disease stages. Additional
derivation of the MID for use in individual patient care and
exploration of valid anchors of global change are needed.
Modifications to the scoring format and potential removal of
the Healthcare Support subscale may be warranted, subject
to further testing. The study was the first to apply General-
izability theory to establish test–retest reliability and sta-
bility of scores in frequent measurements in medicine.
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